David Zuech, MD
Ophthalmology · Enid, OKNPI 1861499071
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Omeros Corporation accounts for 67.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $3,208 and has fallen 89.7% since, to $329 in 2025.
Across 61 payments — averaging $71.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Omeros Corporation$3K
- Alcon$648
- AbbVie$194
- Shire North American Group Inc$156
- Glaukos Corporation$98
- Astellas Pharma US Inc$76
- plus $256 from 10 others
What the payments were for
- Speaking & faculty fees$2,50058%
- Travel & lodging$2486%
- Food & beverage$1,59137%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Omeros Corporation | 7 | $2,910 |
| Alcon | 18 | $648 |
| AbbVie(2 entities) | 10 | $194 |
| Shire North American Group Inc | 6 | $156 |
| Glaukos Corporation | 3 | $98 |
| Astellas Pharma US Inc | 3 | $76 |
| Ocular Therapeutix, Inc. | 4 | $60 |
| Tarsus Pharmaceuticals, Inc. | 2 | $49 |
| The Cameron-ehlen Group, Inc. | 1 | $27 |
| Amgen | 1 | $25 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Merz North America, Inc. | 1 | $19 |
| Harrow Eye, LLC | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $14 |
| Optos, Inc. | 1 | $12 |
| Katena Products, Inc. (dba Corza Medical) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMIDRIA$2,776
- Clareon PanOptix Pro$123
- XIIDRA$118
- AcrySof IQ PanOptix$114
How this compares
$4,338 in reported general payments places this provider in the 85th percentile of 183 ophthalmology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 23 | $18,344 |
| Prednisolone Acetate | 262 | $7,913 |
| LumiganBimatoprost | 13 | $6,213 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $5,651 |
| Travoprost | 23 | $4,104 |
| ZioptanTafluprost/Pf | 12 | $3,063 |
| Ofloxacin | 247 | $3,050 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $2,944 |
| Diclofenac Sodium | 249 | $2,767 |
| Alphagan PBrimonidine Tartrate | 12 | $2,231 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,484 |
| Latanoprost | 103 | $1,231 |
| Brimonidine Tartrate | 59 | $707 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 12 | $456 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 27 | $331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $194 | $14,09552 claims |
| AlconSimbrinza | $648 | $2,94415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 183 ophthalmology providers in Oklahoma.
Other ophthalmology in Enid
- Kyle RogersEnid$19K
- Ronald RebenitschOklahoma City$141K
- Don NguyenEdmond$36K
- Bradley BrittonEdmond$25K
- Edward JonesOklahoma City$13K
- John BelardoOklahoma City$12K
- David KorberOklahoma City$11K
- Jeffrey ShaverEdmond$11K
- Shehzad BatliwalaTulsa$11K
- Whitney PotterEdmond$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.